Attention Deficit Hyperactivity Disorder
Conditions
Keywords
ADHD
Brief summary
For children and adolescents, how does SPD503 compare to placebo for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
Interventions
Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.
DRUGAtomoxetine Hydrochloride
Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose
DRUGPlacebo Comparator
Placebo
Sponsors
Shire
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female, aged 6 17 years at the time of consent/assent at Screening (Visit 1). 2. Subject's parent or legally authorised representative (LAR) must provide signature of informed consent, and there must be documentation of assent (if applicable) by the subject indicating that the subject is aware of the investigational nature of the study and the required procedures and restrictions in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidance E6, and applicable regulations before completing any study related procedures at Screening (Visit 1). 3. Subject meets Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria for a primary diagnosis of ADHD, combined sub-type, hyperactive/impulsive sub-type, or inattentive sub-type based on a detailed psychiatric evaluation using the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime version (K-SADS-PL). 4. Subject has a minimum ADHD-RS-IV total score of 32 at Baseline (Visit 2). 5. Subject has a minimum CGI-S score of 4 at Baseline (Visit 2). 6. Subject is functioning at an age-appropriate level intellectually, as judged by the Investigator. 7. Subject and parent/LAR understand, are willing, able, and likely to fully comply with the study procedures and restrictions defined in this protocol. 8. Subject is able to swallow intact tablets and capsules. 9. Subject who is a female of child-bearing potential (FOCP), defined as greater than or equal to 9 years of age or \<9 years of age and is menarchal, must have a negative serum beta Human Chorionic Gonadotropin (hCG) pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2) and agree to comply with any applicable contraceptive requirements of the protocol. 10. Subject has supine and standing blood pressure (BP) measurement within the 95th percentile for age, sex, and height
Exclusion criteria
1. Subject has a current, controlled (requiring a prohibited medication or behavioural modification program) or uncontrolled, co-morbid psychiatric diagnosis \[except oppositional defiant disorder (ODD)\], including any severe co-morbid Axis II disorders or severe Axis I disorders such as post traumatic stress disorder (PTSD), bipolar illness, psychosis, pervasive developmental disorder, obsessive-compulsive disorder (OCD), substance abuse disorder, or other symptomatic manifestations or lifetime history of bipolar illness, psychosis or conduct disorder that, in the opinion of the Investigator, contraindicate treatment with SPD503 or STRATTERA or confound efficacy or safety assessments. 2. Subject is well-controlled on their current medication, with acceptable tolerability, and the parent/caregiver does not object to the current medication. 3. Subject has any condition or illness including a clinically significant abnormal Screening (Visit 1) laboratory values which, in the opinion of the Investigator, represents an inappropriate risk to the subject and/or could confound the interpretation of the study. Mild stable asthma treated without the use of beta-2 agonist is not exclusionary. 4. Subject has a known history or presence of structural cardiac abnormalities, cardiovascular or cerebrovascular disease, serious heart rhythm abnormalities, syncope, tachycardia, cardiac conduction problems (eg, clinically significant heart block or QT interval prolongation), exercise-related cardiac events including syncope and pre syncope, or clinically significant bradycardia. 5. Subject has a known family history of sudden cardiac death, ventricular arrhythmia, or QT prolongation. 6. Subjects with orthostatic hypotension or a known history of hypertension. 7. Subject has glaucoma. 8. Subject has clinically significant ECG findings as judged by the Investigator with consideration of the central ECG laboratory's interpretation. 9. Subject has a history of a seizure disorder (other than a single childhood febrile seizure occurring before the age of 3 years) or the presence of a serious tic disorder including Tourette's Syndrome. 10. Current use of any prohibited medication or other medications, including monoamine oxidase inhibitors, herbal supplements, that affect BP or heart rate potent CYP2D6 inhibitors, medications known to prolong the QT/QTc interval, medications that lower seizure threshold, pressor agents, beta-2 agonists, medications that affect noradrenaline, medications that have central nervous system (CNS) effects or affect cognitive performance, such as sedating antihistamines and decongestant sympathomimetics (inhaled bronchodilators are permitted) or a history of chronic use of sedating medications \[ie, antihistamines\]) in violation of the protocol specified washout criteria at Baseline (Visit 2). 11. Subject has a history of alcohol or other substance abuse or dependence, as defined by DSM-IV (with the exception of nicotine) within the last 6 months. 12. Subject has taken another investigational product within 30 days prior to Baseline (Visit 2). 13. Subject is significantly overweight based on Center for Disease Control and Prevention Body Mass Index (BMI)-for-age gender specific charts at the Screening (Visit 1). Significantly overweight is defined as a BMI \>95th percentile. 14. Children aged 6 12 years with a body weight of less than 25kg or adolescents aged 13 17 years with a body weight of less than 34kg or greater than 91kg at Screening (Visit 1). 15. Subject has a known or suspected allergy, hypersensitivity, or clinically significant intolerance to guanfacine hydrochloride or atomoxetine hydrochloride, or any components found in SPD503 or STRATTERA. 16. Clinically important abnormality on drug and alcohol screen (excluding the subject's current ADHD stimulant if applicable) at Screening (Visit 1) 17. Subject is female and is pregnant or currently lactating. 18. Subject failed screening or was previously enrolled in this study. 19. Subject is currently considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or has a prior history of, or is currently demonstrating active suicide ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the Investigator. 20. History of failure to respond to an adequate trial of an α2-agonist or atomoxetine hydrochloride for the treatment of ADHD (consisting of an appropriate dose and adequate duration of therapy in the opinion of the investigator). 21. Subjects with renal or hepatic insufficiency.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 10/13 - Last Observation Carried Forward (LOCF) | Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years | The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores | Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years | Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years. |
| Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Learning and School Domain Scores at Week 10/13 - LOCF | Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years | The WFIRS-P Learning in School Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years. |
| Change From Baseline in the WFIRS-P Family Domain Score at Week 10/13 - LOCF | Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years | The WFIRS-P Family Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years. |
| Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years | CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill). Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years. |
| Health Utilities Index-2/3 (HUI 2/3) Scores - LOCF | Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years | HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years. |
| Change From Baseline in the WFIRS-P Global Score at Week 10/13 - LOCF | Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years | The WFIRS-P Global Score is the mean of 50 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years. |
| Change From Baseline in the WFIRS-P Academic Performance Domain Score at Week 10/13 - LOCF | Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years | The WFIRS-P Academic Performance Domain is the mean of 4 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years. |
| Change From Baseline in the WFIRS-P Behavior in School Domain Score at Week 10/13 - LOCF | Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years | The WFIRS-P Behavior in School Domain is the mean of 6 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years. |
| Change From Baseline in the WFIRS-P Life Skills Domain Score at Week 10/13 - LOCF | Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years | The WFIRS-P Life Skills Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years. |
| Change From Baseline in the WFIRS-P Child Self-Concept Domain Score at Week 10/13 - LOCF | Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years | The WFIRS-P Child Self-Concept Domain is the mean of 3 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years. |
| Change From Baseline in the WFIRS-P Social Domain Score at Week 10/13 - LOCF | Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years | The WFIRS-P Social Domain is the mean of 7 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years. |
| Change From Baseline in the WFIRS-P Risk Domain Score at Week 10/13 - LOCF | Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years | The WFIRS-P Risk Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years. |
| Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Weeks 10/13 - LOCF | Baseline and up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years | The BPRS-C characterizes childhood behavioral and emotional symptomatology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years. |
| Structure Side-Effect Questionnaire | Up to 12 weeks for children aged 6-12 years and up to 15 weeks for adolescents aged 13-17 years | The Structured Side-effect Questionnaire is a simple checklist of 17 side effects. The subject indicates whether a side effect has occurred since the last visit by marking 'yes' on the checklist for each of the events listed. Outcome measure is at 12 weeks for ages 6-12 years and at 15 weeks for ages 13-17 years. |
| Columbia-Suicide Severity Rating Scale (C-SSRS) | Up to 12 weeks for children aged 6-12 years and up to 15 weeks for adolescents aged 13-17 years | C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale. Outcome measure is at 12 weeks for ages 6-12 years and at 15 weeks for ages 13-17 years. |
Countries
Austria, Canada, France, Germany, Ireland, Italy, Poland, Romania, Spain, Sweden, Ukraine, United Kingdom, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo Once daily | 111 |
| Guanfacine Hydrochloride Tablet, once daily, optimised dose (1mg to 7mg based on age and weight) | 114 |
| Atomoxetine Hydrochloride Capsule, once daily, optimised dose (10mg to 100mg based on weight) | 112 |
| Total | 337 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 9 | 5 |
| Overall Study | Lack of Efficacy | 14 | 5 | 5 |
| Overall Study | Lost to Follow-up | 0 | 6 | 3 |
| Overall Study | Other | 0 | 0 | 1 |
| Overall Study | Withdrawal by Subject | 4 | 4 | 9 |
Baseline characteristics
| Characteristic | Placebo | Total | Atomoxetine Hydrochloride | Guanfacine Hydrochloride |
|---|---|---|---|---|
| Age, Continuous | 11.0 Years STANDARD_DEVIATION 2.76 | 10.8 Years STANDARD_DEVIATION 2.78 | 10.5 Years STANDARD_DEVIATION 2.81 | 10.9 Years STANDARD_DEVIATION 2.77 |
| Age, Customized 13-17 years | 32 Participants | 95 Participants | 30 Participants | 33 Participants |
| Age, Customized 6-12 years | 79 Participants | 242 Participants | 82 Participants | 81 Participants |
| Region of Enrollment AUSTRIA | 2 Participants | 11 Participants | 5 Participants | 4 Participants |
| Region of Enrollment CANADA | 6 Participants | 19 Participants | 6 Participants | 7 Participants |
| Region of Enrollment FRANCE | 2 Participants | 6 Participants | 2 Participants | 2 Participants |
| Region of Enrollment GERMANY | 23 Participants | 68 Participants | 22 Participants | 23 Participants |
| Region of Enrollment IRELAND | 0 Participants | 2 Participants | 1 Participants | 1 Participants |
| Region of Enrollment ITALY | 5 Participants | 13 Participants | 4 Participants | 4 Participants |
| Region of Enrollment POLAND | 11 Participants | 37 Participants | 12 Participants | 14 Participants |
| Region of Enrollment ROMANIA | 5 Participants | 14 Participants | 6 Participants | 3 Participants |
| Region of Enrollment SPAIN | 16 Participants | 51 Participants | 17 Participants | 18 Participants |
| Region of Enrollment SWEDEN | 1 Participants | 4 Participants | 2 Participants | 1 Participants |
| Region of Enrollment UKRAINE | 21 Participants | 54 Participants | 15 Participants | 18 Participants |
| Region of Enrollment UNITED KINGDOM | 1 Participants | 2 Participants | 1 Participants | 0 Participants |
| Region of Enrollment UNITED STATES | 18 Participants | 56 Participants | 19 Participants | 19 Participants |
| Sex: Female, Male Female | 25 Participants | 88 Participants | 25 Participants | 38 Participants |
| Sex: Female, Male Male | 86 Participants | 249 Participants | 87 Participants | 76 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 62 / 111 | 79 / 114 | 67 / 112 |
| serious Total, serious adverse events | 1 / 111 | 1 / 114 | 0 / 112 |
Outcome results
Primary
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 10/13 - Last Observation Carried Forward (LOCF)
The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.
Time frame: Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Population: Full Analysis Set (FAS) defined as all randomized subjects who took at least 1 dose of investigational product. If more than 20% of the items used for summing a score were missing, the score was set to missing.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 10/13 - Last Observation Carried Forward (LOCF) | -15.0 units on a scale | Standard Error 1.1612 |
| Guanfacine Hydrochloride | Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 10/13 - Last Observation Carried Forward (LOCF) | -23.9 units on a scale | Standard Error 1.1531 |
| Atomoxetine Hydrochloride | Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 10/13 - Last Observation Carried Forward (LOCF) | -18.8 units on a scale | Standard Error 1.1549 |
p-value: <0.00195% CI: [-11.9, -5.8]ANCOVA
p-value: 0.01795% CI: [-6.8, -0.7]ANCOVA
Secondary
Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Weeks 10/13 - LOCF
The BPRS-C characterizes childhood behavioral and emotional symptomatology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.
Time frame: Baseline and up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Population: Safety Population defined as of randomized subjects who took at least 1 dose of investigational product.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Weeks 10/13 - LOCF | -5.6 units on a scale | Standard Deviation 8.82 |
| Guanfacine Hydrochloride | Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Weeks 10/13 - LOCF | -8.3 units on a scale | Standard Deviation 8.4 |
| Atomoxetine Hydrochloride | Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Weeks 10/13 - LOCF | -6.5 units on a scale | Standard Deviation 9.23 |
Secondary
Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Learning and School Domain Scores at Week 10/13 - LOCF
The WFIRS-P Learning in School Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.
Time frame: Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Population: Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Learning and School Domain Scores at Week 10/13 - LOCF | -0.419 units on a scale | Standard Error 0.0537 |
| Guanfacine Hydrochloride | Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Learning and School Domain Scores at Week 10/13 - LOCF | -0.636 units on a scale | Standard Error 0.0527 |
| Atomoxetine Hydrochloride | Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Learning and School Domain Scores at Week 10/13 - LOCF | -0.581 units on a scale | Standard Error 0.0534 |
p-value: 0.00395% CI: [-0.358, -0.076]ANCOVA
p-value: 0.02695% CI: [-0.305, -0.019]ANCOVA
Secondary
Change From Baseline in the WFIRS-P Academic Performance Domain Score at Week 10/13 - LOCF
The WFIRS-P Academic Performance Domain is the mean of 4 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.
Time frame: Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Population: Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the WFIRS-P Academic Performance Domain Score at Week 10/13 - LOCF | -0.555 units on a scale | Standard Error 0.0784 |
| Guanfacine Hydrochloride | Change From Baseline in the WFIRS-P Academic Performance Domain Score at Week 10/13 - LOCF | -0.766 units on a scale | Standard Error 0.0757 |
| Atomoxetine Hydrochloride | Change From Baseline in the WFIRS-P Academic Performance Domain Score at Week 10/13 - LOCF | -0.681 units on a scale | Standard Error 0.0759 |
p-value: 0.04395% CI: [-0.416, -0.007]ANCOVA
p-value: 0.23195% CI: [-0.331, 0.08]ANCOVA
Secondary
Change From Baseline in the WFIRS-P Behavior in School Domain Score at Week 10/13 - LOCF
The WFIRS-P Behavior in School Domain is the mean of 6 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.
Time frame: Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Population: Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the WFIRS-P Behavior in School Domain Score at Week 10/13 - LOCF | -0.363 units on a scale | Standard Error 0.0512 |
| Guanfacine Hydrochloride | Change From Baseline in the WFIRS-P Behavior in School Domain Score at Week 10/13 - LOCF | -0.592 units on a scale | Standard Error 0.0502 |
| Atomoxetine Hydrochloride | Change From Baseline in the WFIRS-P Behavior in School Domain Score at Week 10/13 - LOCF | -0.544 units on a scale | Standard Error 0.0509 |
p-value: <0.00195% CI: [-0.364, -0.094]ANCOVA
p-value: 0.00995% CI: [-0.317, -0.045]ANCOVA
Secondary
Change From Baseline in the WFIRS-P Child Self-Concept Domain Score at Week 10/13 - LOCF
The WFIRS-P Child Self-Concept Domain is the mean of 3 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.
Time frame: Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Population: Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the WFIRS-P Child Self-Concept Domain Score at Week 10/13 - LOCF | -0.312 units on a scale | Standard Error 0.0544 |
| Guanfacine Hydrochloride | Change From Baseline in the WFIRS-P Child Self-Concept Domain Score at Week 10/13 - LOCF | -0.361 units on a scale | Standard Error 0.0528 |
| Atomoxetine Hydrochloride | Change From Baseline in the WFIRS-P Child Self-Concept Domain Score at Week 10/13 - LOCF | -0.390 units on a scale | Standard Error 0.0536 |
p-value: 0.595% CI: [-0.191, 0.094]ANCOVA
p-value: 0.28895% CI: [-0.222, 0.066]ANCOVA
Secondary
Change From Baseline in the WFIRS-P Family Domain Score at Week 10/13 - LOCF
The WFIRS-P Family Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.
Time frame: Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Population: Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the WFIRS-P Family Domain Score at Week 10/13 - LOCF | -0.409 units on a scale | Standard Error 0.0568 |
| Guanfacine Hydrochloride | Change From Baseline in the WFIRS-P Family Domain Score at Week 10/13 - LOCF | -0.617 units on a scale | Standard Error 0.0558 |
| Atomoxetine Hydrochloride | Change From Baseline in the WFIRS-P Family Domain Score at Week 10/13 - LOCF | -0.499 units on a scale | Standard Error 0.0566 |
p-value: 0.00695% CI: [-0.358, -0.059]ANCOVA
p-value: 0.24295% CI: [-0.241, 0.061]ANCOVA
Secondary
Change From Baseline in the WFIRS-P Global Score at Week 10/13 - LOCF
The WFIRS-P Global Score is the mean of 50 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.
Time frame: Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Population: Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the WFIRS-P Global Score at Week 10/13 - LOCF | -0.321 units on a scale | Standard Error 0.0387 |
| Guanfacine Hydrochloride | Change From Baseline in the WFIRS-P Global Score at Week 10/13 - LOCF | -0.487 units on a scale | Standard Error 0.0374 |
| Atomoxetine Hydrochloride | Change From Baseline in the WFIRS-P Global Score at Week 10/13 - LOCF | -0.425 units on a scale | Standard Error 0.0384 |
p-value: 0.00195% CI: [-0.266, -0.064]ANCOVA
p-value: 0.04895% CI: [-0.207, -0.001]ANCOVA
Secondary
Change From Baseline in the WFIRS-P Life Skills Domain Score at Week 10/13 - LOCF
The WFIRS-P Life Skills Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.
Time frame: Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Population: Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the WFIRS-P Life Skills Domain Score at Week 10/13 - LOCF | -0.383 units on a scale | Standard Error 0.0422 |
| Guanfacine Hydrochloride | Change From Baseline in the WFIRS-P Life Skills Domain Score at Week 10/13 - LOCF | -0.477 units on a scale | Standard Error 0.0411 |
| Atomoxetine Hydrochloride | Change From Baseline in the WFIRS-P Life Skills Domain Score at Week 10/13 - LOCF | -0.450 units on a scale | Standard Error 0.0422 |
p-value: 0.09695% CI: [-0.204, 0.017]ANCOVA
p-value: 0.24295% CI: [-0.18, 0.046]ANCOVA
Secondary
Change From Baseline in the WFIRS-P Risk Domain Score at Week 10/13 - LOCF
The WFIRS-P Risk Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.
Time frame: Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Population: Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the WFIRS-P Risk Domain Score at Week 10/13 - LOCF | -0.134 units on a scale | Standard Error 0.0284 |
| Guanfacine Hydrochloride | Change From Baseline in the WFIRS-P Risk Domain Score at Week 10/13 - LOCF | -0.190 units on a scale | Standard Error 0.0275 |
| Atomoxetine Hydrochloride | Change From Baseline in the WFIRS-P Risk Domain Score at Week 10/13 - LOCF | -0.173 units on a scale | Standard Error 0.0285 |
p-value: 0.13995% CI: [-0.131, 0.018]ANCOVA
p-value: 0.31595% CI: [-0.115, 0.037]ANCOVA
Secondary
Change From Baseline in the WFIRS-P Social Domain Score at Week 10/13 - LOCF
The WFIRS-P Social Domain is the mean of 7 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.
Time frame: Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Population: Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the WFIRS-P Social Domain Score at Week 10/13 - LOCF | -0.322 units on a scale | Standard Error 0.0537 |
| Guanfacine Hydrochloride | Change From Baseline in the WFIRS-P Social Domain Score at Week 10/13 - LOCF | -0.555 units on a scale | Standard Error 0.0519 |
| Atomoxetine Hydrochloride | Change From Baseline in the WFIRS-P Social Domain Score at Week 10/13 - LOCF | -0.434 units on a scale | Standard Error 0.0532 |
p-value: 0.00195% CI: [-0.374, -0.092]ANCOVA
p-value: 0.12495% CI: [-0.253, 0.031]ANCOVA
Secondary
Clinical Global Impression-Severity of Illness (CGI-S) - LOCF
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill). Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.
Time frame: Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Population: Full Analysis Set. Not all subjects in the FAS population had data for this outcome.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 2 (Borderline mentally ill) | 15.3 percentage of participants |
| Placebo | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 5 (Markedly ill) | 25.2 percentage of participants |
| Placebo | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 4 (Moderately ill) | 20.7 percentage of participants |
| Placebo | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 1 (Normal, not at all ill) | 9.9 percentage of participants |
| Placebo | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 7 (Amongst the most extremely ill) | 1.8 percentage of participants |
| Placebo | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 6 (Severely ill) | 6.3 percentage of participants |
| Placebo | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 3 (Mildly ill) | 20.7 percentage of participants |
| Guanfacine Hydrochloride | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 4 (Moderately ill) | 22.3 percentage of participants |
| Guanfacine Hydrochloride | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 1 (Normal, not at all ill) | 14.3 percentage of participants |
| Guanfacine Hydrochloride | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 2 (Borderline mentally ill) | 23.2 percentage of participants |
| Guanfacine Hydrochloride | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 3 (Mildly ill) | 31.3 percentage of participants |
| Guanfacine Hydrochloride | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 5 (Markedly ill) | 5.4 percentage of participants |
| Guanfacine Hydrochloride | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 6 (Severely ill) | 3.6 percentage of participants |
| Guanfacine Hydrochloride | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 7 (Amongst the most extremely ill) | 0 percentage of participants |
| Atomoxetine Hydrochloride | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 5 (Markedly ill) | 13.4 percentage of participants |
| Atomoxetine Hydrochloride | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 2 (Borderline mentally ill) | 19.6 percentage of participants |
| Atomoxetine Hydrochloride | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 7 (Amongst the most extremely ill) | 1.8 percentage of participants |
| Atomoxetine Hydrochloride | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 6 (Severely ill) | 7.1 percentage of participants |
| Atomoxetine Hydrochloride | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 4 (Moderately ill) | 19.6 percentage of participants |
| Atomoxetine Hydrochloride | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 3 (Mildly ill) | 32.1 percentage of participants |
| Atomoxetine Hydrochloride | Clinical Global Impression-Severity of Illness (CGI-S) - LOCF | 1 (Normal, not at all ill) | 6.3 percentage of participants |
p-value: <0.001Cochran-Mantel-Haenszel
p-value: 0.196Cochran-Mantel-Haenszel
Secondary
Columbia-Suicide Severity Rating Scale (C-SSRS)
C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale. Outcome measure is at 12 weeks for ages 6-12 years and at 15 weeks for ages 13-17 years.
Time frame: Up to 12 weeks for children aged 6-12 years and up to 15 weeks for adolescents aged 13-17 years
Population: SP
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Columbia-Suicide Severity Rating Scale (C-SSRS) | Suicidal Ideation | 2 participants |
| Placebo | Columbia-Suicide Severity Rating Scale (C-SSRS) | Suicidal Behaviour | 0 participants |
| Guanfacine Hydrochloride | Columbia-Suicide Severity Rating Scale (C-SSRS) | Suicidal Ideation | 3 participants |
| Guanfacine Hydrochloride | Columbia-Suicide Severity Rating Scale (C-SSRS) | Suicidal Behaviour | 0 participants |
| Atomoxetine Hydrochloride | Columbia-Suicide Severity Rating Scale (C-SSRS) | Suicidal Ideation | 5 participants |
| Atomoxetine Hydrochloride | Columbia-Suicide Severity Rating Scale (C-SSRS) | Suicidal Behaviour | 0 participants |
Secondary
Health Utilities Index-2/3 (HUI 2/3) Scores - LOCF
HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.
Time frame: Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Population: Full Analysis Set. Not all subjects in the FAS population had data for this outcome.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Health Utilities Index-2/3 (HUI 2/3) Scores - LOCF | 0.927 units on a scale | Standard Deviation 0.095 |
| Guanfacine Hydrochloride | Health Utilities Index-2/3 (HUI 2/3) Scores - LOCF | 0.922 units on a scale | Standard Deviation 0.0908 |
| Atomoxetine Hydrochloride | Health Utilities Index-2/3 (HUI 2/3) Scores - LOCF | 0.913 units on a scale | Standard Deviation 0.1052 |
Secondary
Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.
Time frame: Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Population: Full Analysis Set. Not all subjects in the FAS population had data for this outcome.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores | 44.1 percentage of participants |
| Guanfacine Hydrochloride | Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores | 67.9 percentage of participants |
| Atomoxetine Hydrochloride | Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores | 56.3 percentage of participants |
p-value: <0.00195% CI: [11.1, 36.4]Cochran-Mantel-Haenszel
p-value: 0.02495% CI: [-0.9, 25.1]Cochran-Mantel-Haenszel
Secondary
Structure Side-Effect Questionnaire
The Structured Side-effect Questionnaire is a simple checklist of 17 side effects. The subject indicates whether a side effect has occurred since the last visit by marking 'yes' on the checklist for each of the events listed. Outcome measure is at 12 weeks for ages 6-12 years and at 15 weeks for ages 13-17 years.
Time frame: Up to 12 weeks for children aged 6-12 years and up to 15 weeks for adolescents aged 13-17 years
Population: Safety Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Structure Side-Effect Questionnaire | Insomnia | 19 participants |
| Placebo | Structure Side-Effect Questionnaire | Somnolence | 26 participants |
| Placebo | Structure Side-Effect Questionnaire | Vomiting | 11 participants |
| Placebo | Structure Side-Effect Questionnaire | Depression | 7 participants |
| Placebo | Structure Side-Effect Questionnaire | Decreased Appetite | 25 participants |
| Placebo | Structure Side-Effect Questionnaire | Itching | 7 participants |
| Placebo | Structure Side-Effect Questionnaire | Rash | 4 participants |
| Placebo | Structure Side-Effect Questionnaire | Missed Menses | 0 participants |
| Placebo | Structure Side-Effect Questionnaire | Increased Appetite | 30 participants |
| Placebo | Structure Side-Effect Questionnaire | Headache | 35 participants |
| Placebo | Structure Side-Effect Questionnaire | Diarrhea | 15 participants |
| Placebo | Structure Side-Effect Questionnaire | Dizziness | 16 participants |
| Placebo | Structure Side-Effect Questionnaire | Fatigue | 30 participants |
| Placebo | Structure Side-Effect Questionnaire | Nausea | 19 participants |
| Placebo | Structure Side-Effect Questionnaire | Nervousnes/Anxiety | 25 participants |
| Placebo | Structure Side-Effect Questionnaire | Abdominal Pain | 26 participants |
| Guanfacine Hydrochloride | Structure Side-Effect Questionnaire | Diarrhea | 18 participants |
| Guanfacine Hydrochloride | Structure Side-Effect Questionnaire | Abdominal Pain | 45 participants |
| Guanfacine Hydrochloride | Structure Side-Effect Questionnaire | Increased Appetite | 40 participants |
| Guanfacine Hydrochloride | Structure Side-Effect Questionnaire | Somnolence | 57 participants |
| Guanfacine Hydrochloride | Structure Side-Effect Questionnaire | Nausea | 30 participants |
| Guanfacine Hydrochloride | Structure Side-Effect Questionnaire | Insomnia | 32 participants |
| Guanfacine Hydrochloride | Structure Side-Effect Questionnaire | Depression | 7 participants |
| Guanfacine Hydrochloride | Structure Side-Effect Questionnaire | Headache | 52 participants |
| Guanfacine Hydrochloride | Structure Side-Effect Questionnaire | Fatigue | 55 participants |
| Guanfacine Hydrochloride | Structure Side-Effect Questionnaire | Decreased Appetite | 31 participants |
| Guanfacine Hydrochloride | Structure Side-Effect Questionnaire | Nervousnes/Anxiety | 37 participants |
| Guanfacine Hydrochloride | Structure Side-Effect Questionnaire | Rash | 9 participants |
| Guanfacine Hydrochloride | Structure Side-Effect Questionnaire | Vomiting | 7 participants |
| Guanfacine Hydrochloride | Structure Side-Effect Questionnaire | Dizziness | 28 participants |
| Guanfacine Hydrochloride | Structure Side-Effect Questionnaire | Missed Menses | 1 participants |
| Guanfacine Hydrochloride | Structure Side-Effect Questionnaire | Itching | 13 participants |
| Atomoxetine Hydrochloride | Structure Side-Effect Questionnaire | Missed Menses | 0 participants |
| Atomoxetine Hydrochloride | Structure Side-Effect Questionnaire | Nausea | 39 participants |
| Atomoxetine Hydrochloride | Structure Side-Effect Questionnaire | Vomiting | 25 participants |
| Atomoxetine Hydrochloride | Structure Side-Effect Questionnaire | Diarrhea | 8 participants |
| Atomoxetine Hydrochloride | Structure Side-Effect Questionnaire | Abdominal Pain | 42 participants |
| Atomoxetine Hydrochloride | Structure Side-Effect Questionnaire | Decreased Appetite | 48 participants |
| Atomoxetine Hydrochloride | Structure Side-Effect Questionnaire | Increased Appetite | 25 participants |
| Atomoxetine Hydrochloride | Structure Side-Effect Questionnaire | Headache | 34 participants |
| Atomoxetine Hydrochloride | Structure Side-Effect Questionnaire | Dizziness | 23 participants |
| Atomoxetine Hydrochloride | Structure Side-Effect Questionnaire | Fatigue | 35 participants |
| Atomoxetine Hydrochloride | Structure Side-Effect Questionnaire | Nervousnes/Anxiety | 34 participants |
| Atomoxetine Hydrochloride | Structure Side-Effect Questionnaire | Insomnia | 24 participants |
| Atomoxetine Hydrochloride | Structure Side-Effect Questionnaire | Somnolence | 38 participants |
| Atomoxetine Hydrochloride | Structure Side-Effect Questionnaire | Depression | 9 participants |
| Atomoxetine Hydrochloride | Structure Side-Effect Questionnaire | Itching | 10 participants |
| Atomoxetine Hydrochloride | Structure Side-Effect Questionnaire | Rash | 8 participants |